Is There Any Effective Replacement For Cholesterol Lowering Drug Statins?

.

Is There Any Effective Replacement For Cholesterol Lowering Drug Statins?

While there is hardly any doubt left that high cholesterol does no good to any one, a recent research has raised hopes of patients. Though there are drugs like statins which can cut off the risk of death due to the same, it has been found that it cannot save all patients with as many as 10% of the patients suffering from its negative consequences. In addition, there are many who are unable to get the chief benefit of the drug to lower down their LDL-C, or "bad cholesterol”.

Perhaps this is what made researchers to develop a new class of cholesterol-busting medication which could change the future course for patients. In the name of REGN727 under PCSK9 inhibitors, the drug could considerably reduce cholesterol by 65% in healthy ones. Another fascinating part of the drug was that it could reduce bad cholesterol by 61% in those who were already taking atorvastatin, a powerful cholesterol-lowering medication. With no side effects identified so far, there is need that this drug is being considered for the treatment.

If the lead author of the study, Dr. Evan Stein of the Metabolic and Atherosclerosis Research Center in Cincinnati, is to be heard, there are fair chances that this drug could surpass the benefits attached with popularly used statins in near future.

"Inhibitors of PCSK9 are perhaps the most exciting new approach to LDL-lowering based on very strong human genetics supporting the efficacy and safety of this approach”, said Dr. Dan Rader, a Professor of medicine at the University of Pennsylvania, who is also acting as a consultant for the pharmaceutical companies, Regeneron and Sanofi, which are supporting the study.

While the research published in the New England Journal of Medicine is being getting the attention of one and all, there are hopes raised that there might be some sort of effective replacement for statins developed in the time to come.


Latest News

Rise in Russian Arms Sales In spite of a Drop Globally
PetSmart Sells itself with an $8.3Billion Deal
Falling Oil Prices Result in a Drop in Stocks
Shares of Amaya Fall Due to Probe Conducted by Securities Regulators
Americans Consumers Display Confidence In the Market with Gain in Sales
It’s Time to Hurry Up to Enrol in the First Phase of Affordable Care Act Health
After Merger with Alliance Boots,	Walgreen CEO will Retire
Falling Fuel Prices Lift Airline Profits But No Respite in Fares Expected
Citigroup to Pay Likely $2.7B as Legal Charge
Michael Jeffries Retires as the CEO of Abercrombie & Fitch
Deutsche Bank in Trouble Again in the U.S. for Alleged Tax Scheme
Popular Demand Brings French Toast Crunch Back on the Shelves